For some people with inflammatory bowel disease, conventional treatment does not adequately control intestinal inflammation. In these situations, biologic medicines may form part of a more advanced treatment strategy. Infliximab is one such therapy used for selected patients with Crohn's disease and ulcerative colitis.
Understanding what the medicine does, why screening is needed and how response is monitored can make treatment discussions easier.
What is infliximab?
Infliximab is a biologic medicine that targets tumour necrosis factor alpha, commonly abbreviated as TNF-alpha. This inflammatory protein plays a role in immune activity and can contribute to inflammation in conditions such as Crohn's disease and ulcerative colitis.
By blocking TNF-alpha, infliximab can help reduce inflammatory activity in appropriately selected patients.
It is not a general medicine for every episode of diarrhoea or abdominal discomfort.
When might it be considered?
The decision depends on the type and severity of IBD, previous treatments, complications and individual clinical circumstances.
It may be considered when active inflammatory bowel disease requires stronger control or when other treatment strategies have not provided an adequate response.
The presence of specific Crohn's disease complications can also influence biologic treatment decisions.
Why is screening required beforehand?
Biologic medicines modify immune activity. That makes pre-treatment assessment important.
Before starting infliximab, clinicians typically review the patient's infection history and assess for important infections such as tuberculosis and hepatitis B according to appropriate medical protocols.
This has particular relevance in India, where assessment for latent or previous tuberculosis exposure can be an important component of biologic treatment planning.
Vaccination history and other medical conditions may also need review.
Patients should provide their treating doctor with a complete list of medicines and disclose previous serious infections.
How is treatment given?
Infliximab is administered intravenously. Treatment generally includes initial induction doses followed by maintenance therapy according to the prescribed schedule.
Patients should understand that feeling better does not necessarily mean treatment can be stopped independently. IBD management aims to control underlying inflammatory activity and maintain remission, not merely provide short-term relief.
What happens if symptoms return?
A change in symptoms while receiving biologic treatment does not always mean the medicine has completely stopped working.
Doctors may need to determine whether
- Active intestinal inflammation has returned
- An infection is causing symptoms
- Another digestive problem is present
- Treatment needs optimisation
- A different therapeutic strategy should be considered
In selected circumstances, drug-level or antibody testing may contribute to treatment decisions.
Monitoring is part of the treatment
Regular follow-up may involve symptom assessment, blood investigations and objective evaluation of disease activity when indicated.
Patients should also know which symptoms should be reported promptly, particularly signs suggesting significant infection or an infusion-related reaction.
The monitoring plan should be individualised rather than based on a one-size-fits-all schedule.
Making a biologic treatment decision in Mumbai
Starting a biologic can feel like a major step, particularly for patients who have previously managed symptoms with oral medicines. A useful consultation should therefore cover why the treatment is being proposed, its expected role, required screening and how effectiveness will be assessed.
Dr. Harshad Joshi provides gastrointestinal care in Mumbai for inflammatory bowel conditions where advanced therapies such as infliximab may be evaluated when clinically appropriate.
For patients in Mumbai and other parts of Maharashtra considering biologic treatment, the key issue is not whether infliximab is stronger than another medicine. The better question is whether it matches the type, severity and behaviour of the individual patient's IBD.
Appropriate selection, pre-treatment screening and ongoing monitoring are what turn a medication choice into a structured treatment strategy.
